(“Sareum” or “the Company”)

Notice of AGM and Posting of Annual Report & Accounts

Cambridge, UK, 19 November 2020 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that its Annual General Meeting (“AGM”) will be held at 10.00 a.m. on Tuesday 15 December 2020 at the Company’s registered office at 2a Langford Arch, Cambridge CB22 3FX.

In response to the Covid-19 pandemic and in order to ensure the safety of the Company’s shareholders and employees, in accordance with the provisions of the Corporate Insolvency and Governance Act 2020, shareholders may not attend the AGM in person this year. The AGM will be run as a closed meeting.

The Directors recognise the importance of the AGM as an opportunity for shareholders to communicate with Directors and, accordingly, shareholders are invited to listen to the meeting via the Investor Meet Company (IMC) platform and they will be able to raise questions with the Chairman, Chief Executive Officer and Chief Scientific Officer in a Q&A session to be held immediately after the AGM.

Shareholders are reminded that this will not constitute attendance at the AGM and shareholders will not be able to vote on the day of the AGM – details on how to vote are below.

Shareholders wishing to join the AGM remotely and participate in the Q&A session should register with IMC at: Shareholders who have already registered with IMC and requested to meet the Company will be invited automatically.

Questions can be submitted before the event via the IMC dashboard or at any time during the AGM via the “Ask a Question” function. Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market. Responses from the Q&A session will be published at the earliest opportunity on the IMC platform.


As the AGM will be run as a closed meeting, shareholders are urged to vote electronically and to appoint the Chair of the AGM as their proxy.

Shareholders are requested to submit their votes online via the shareholder portal at, where details of the procedures are set out. If shareholders have not done so already, they will need to register their account using their Investor Code, which can be found on their share certificate.

If shareholders hold shares in CREST and wish to vote via Signal Shares rather than the CREST electronic proxy appointment services, please contact the Company’s registrars, Link Asset Services, to obtain their investor code.

Alternatively, shareholders may request a paper form of proxy from the Company’s registrars, Link Asset Services, and details of how to contact them are set out in the Notice of AGM.

In order to vote online, shareholders will need to visit, search ‘Sareum Holdings Plc’ and use their Investor Code to log in or register. Once logged in, click the ‘Vote Online Now’ button and follow the procedure as instructed.

Posting of the Annual Report and Accounts and Notice of AGM

The Notice of AGM, along with a copy of the Company’s Annual Report and Accounts for the year ended 30 June 2020, were posted yesterday to those shareholders who requested a hard copy. A copy of both documents will shortly be available on the Company’s website

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO



01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / Richard Tulloch



020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce / John Beresford-Peirse



020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible


020 7638 9571


About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

The Company’s preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at


- Ends -